🇺🇸 FDA
Company

Aprea

Aprea Therapeutics

APRE pharma USA

Quick answer

Aprea is a pharma company (APRE) headquartered in DOYLESTOWN, PA, USA with 15 tracked pipeline programs.

Pipeline (15)

project

APR-246 + azacitidine

MDS

Phase 3 · small_molecule · completed

1 trials project

APR-246

Acute Myeloid Leukemia or Myelodysplastic Syndromes

Phase 2 · small_molecule · completed

1 trials project

APR-246

Myelodysplastic Syndrome With Gene Mutation

Phase 2 · small_molecule · active

1 trials project

APR-246

Melanoma

Phase 2 · small_molecule · terminated

1 trials project

APR-246

Myelodysplastic Syndrome

Phase 2 · small_molecule · completed

1 trials project

APR-246

Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

Phase 2 · small_molecule · completed

1 trials project

APR-246

High-grade Serous Ovarian Cancer

Phase 2 · small_molecule · completed

1 trials project

APR-246 (eprenetapopt) + Acalabrutinib in CLL

Non Hodgkin Lymphoma

Phase 2 · small_molecule · terminated

1 trials project

APR-246 (eprenetapopt) + Pembrolizumab

Bladder Cancer

Phase 2 · small_molecule · completed

1 trials project

ATRN-119

HPV Positive Oropharyngeal Squamous Cell Carcinoma

Phase 2 · small_molecule · active

1 trials project

ATRN-119

Advanced Solid Tumor

Phase 2 · small_molecule · active

1 trials project

APR-1051

Advanced Solid Tumor

Phase 1 · small_molecule · active

1 trials project

APR-246

Hematologic Neoplasms

Phase 1 · small_molecule · completed

1 trials project

APR-246

Myeloid Malignancy

Phase 1 · small_molecule · completed

1 trials project

APR-548 + Azacitidine

MDS

Phase 1 · small_molecule · terminated

1 trials

Patents (6)

patent

US 9061016

Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferati

Expires Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 7902167

Compounds and methods for down-regulating Wrap53 protein by RNA interference

Expires Mon Mar 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 7759361

Azabicyclooctan-3-one derivatives and use thereof

Expires Mon Jul 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 7659278

Use of low molecular weight compounds for preparing a medicament useful in treat

Expires Mon Feb 04 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 7348330

1-azabicyclo [2,2,2] octan-3-one derivatives

Expires Mon Mar 20 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 6921765

1-Azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their u

Expires Mon Jul 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time)